Has James Marion, MD received payments from drug or device companies?

Yes. Drug and device makers reported $54,222 in general payments to James Marion, MD across 64 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Marion, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Marion, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Marion, MD

Gastroenterology · New York, NYNPI 1306869474

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $46,318 of the $54,222 with a category attached, or 85.4%. Johnson & Johnson accounts for 99.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $16,272 and has fallen 51.2% since, to $7,942 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,222in general payments, 2019–2025

Across 64 payments — averaging $847.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$54K
UCB, Inc.$93
AbbVie$33
Exact Sciences$20

$1,602,772in research payments, 2019–2025

Across 276 payments — averaging $5807.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$1M
Pfizer$354K
AbbVie$212K

What the payments were for

Consulting fees$46,31885%
Travel & lodging$6,10711%
Food & beverage$1,7973%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	61	$54,076
UCB, Inc.	1	$93
AbbVie	1	$33
Exact Sciences	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

STELARA$27,380
Tremfya$25,806

How this compares

$54,222 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$71,981

Medicare patients

296

Services billed

578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StelaraUstekinumab	128	$3,437,768
Humira(Cf) PenAdalimumab	60	$589,944
Skyrizi On-BodyRisankizumab-Rzaa	26	$492,388
RinvoqUpadacitinib	22	$141,953
EntyvioVedolizumab	12	$98,555
XifaxanRifaximin	16	$66,820
Mesalamine	93	$45,672
Mesalamine ErMesalamine	23	$15,988
LinzessLinaclotide	14	$11,413
Mesalamine DrMesalamine	15	$10,565
Budesonide EcBudesonide	34	$5,925
CholestyramineCholestyramine (With Sugar)	25	$2,236
Opium Tincture	16	$2,200
Sulfasalazine DrSulfasalazine	23	$1,956
Sulfasalazine	43	$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara	$54,076	$3,437,768128 claims
AbbVieRinvoq, Linzess	$33	$153,36536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

David Carr LockeNew York$2M
Arthur KornbluthNew York$1.9M
Sonal KumarNew York$1M
David PoppersNew York$939K
Ellen ScherlNew York$857K
Bruce SandsNew York$810K
Jean Frederick ColombelNew York$786K
Seth GrossNew York$624K
Caterina Oneto ArayaNew York$610K
Dana LukinNew York$491K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →